Spero Stock Analysis

SPRO -  USA Stock  

USD 13.20  1.27  10.65%

The latest slide in stock price created some momentum for institutional investors as it was traded today as low as 11.69 and as high as 13.35 per share. The company management teams have failed to build on market volatilities in December. However, diversifying your overall positions with Spero Therapeutics may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.33. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Spero Therapeutics partners.
Additionally, take a look at World Market Map.

Spero Stock Analysis 

 
Refresh
The Spero Therapeutics stock analysis report makes it easy to digest most publicly released information about Spero Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Spero Stock analysis module also helps to analyze the Spero Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Spero Stock Analysis Notes

About 16.0% of the company outstanding shares are owned by corporate insiders. The book value of Spero Therapeutics was at this time reported as 3.47. The company recorded a loss per share of 2.67. Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant bacterial infections and rare diseases in the United States. Spero Therapeutics, Inc. has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries collaboration agreement with Bill Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people. To find out more about Spero Therapeutics contact Ankit Mahadevia at 857 242 1600 or learn more at https://sperotherapeutics.com.

Spero Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Spero Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Spero Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Spero Therapeutics generated a negative expected return over the last 90 days
Spero Therapeutics has high historical volatility and very poor performance
Spero Therapeutics is unlikely to experience financial distress in the next 2 years
The company reported the previous year's revenue of 17.42 M. Net Loss for the year was (79.1 M) with loss before overhead, payroll, taxes, and interest of (57.67 M).
Spero Therapeutics currently holds about 123.42 M in cash with (53.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.82.
Roughly 57.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Purchase by Aquilo Capital Management Llc of 8867 shares of Spero Therapeutics

Spero Therapeutics Upcoming and Recent Events

Earnings reports are used by Spero Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Spero Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report3rd of March 2016
Next Fiscal Quarter End31st of December 2015

Spero Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 426.67 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Spero Therapeutics's market, we take the total number of its shares issued and multiply it by Spero Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (32.84) % which means that it has lost $32.84 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (64.66) %, meaning that it created substantial loss on money invested by shareholders. Spero Therapeutics management efficiency ratios could be used to measure how well spero therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 17th of January 2022, Spero Therapeutics has the risk adjusted performance of (0.08), and Coefficient Of Variation of (879.60). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Spero Therapeutics, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Spero Therapeutics, which can be compared to its competition. Please validate Spero Therapeutics semi deviation, jensen alpha, as well as the relationship between the Jensen Alpha and semi variance to decide if Spero Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 13.2 per share. Given that Spero Therapeutics has jensen alpha of (0.42), we advise you to double-check Spero Therapeutics's current market performance to make sure the company can sustain itself at a future point.

Spero Therapeutics Price Movement Analysis

The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Spero Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Spero Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target. View also all equity analysis or get more info about bollinger bands overlap studies indicator.

Spero Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Spero Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Spero Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Spero Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aquilo Capital Management Llc few days ago via Macroaxis 
Purchase by Aquilo Capital Management Llc of 8867 shares of Spero Therapeutics
Tregoning Kathleen over a week ago via Macroaxis 
Acquisition by Tregoning Kathleen of 4428 shares of Spero Therapeutics subject to Rule 16b-3
Ankit Mahadevia over two weeks ago via Macroaxis 
Exercise or conversion by Ankit Mahadevia of 8000 shares of Spero Therapeutics subject to Rule 16b-3
Tregoning Kathleen over two months ago via Macroaxis 
Acquisition by Tregoning Kathleen of 15000 shares of Spero Therapeutics subject to Rule 16b-3
Aquilo Capital Management Llc over two months ago via Macroaxis 
Purchase by Aquilo Capital Management Llc of 150000 shares of Spero Therapeutics
Aquilo Capital Management Llc over three months ago via Macroaxis 
Purchase by Aquilo Capital Management Llc of 134543 shares of Spero Therapeutics
Aquilo Capital Management Llc over three months ago via Macroaxis 
Purchase by Aquilo Capital Management Llc of 2156 shares of Spero Therapeutics
Aquilo Capital Management Llc over three months ago via Macroaxis 
Purchase by Aquilo Capital Management Llc of 24749 shares of Spero Therapeutics
Aquilo Capital Management Llc over three months ago via Macroaxis 
Purchase by Aquilo Capital Management Llc of 48645 shares of Spero Therapeutics
Timothy Keutzer over three months ago via Macroaxis 
Acquisition by Timothy Keutzer of 24067 shares of Spero Therapeutics subject to Rule 16b-3
Aquilo Capital Management Llc over three months ago via Macroaxis 
Purchase by Aquilo Capital Management Llc of 13957 shares of Spero Therapeutics
Aquilo Capital Management Llc over three months ago via Macroaxis 
Purchase by Aquilo Capital Management Llc of 40170 shares of Spero Therapeutics

Spero Therapeutics Technical and Predictive Indicators

Spero Therapeutics Forecast Models

Spero Therapeutics time-series forecasting models is one of many Spero Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Spero Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Spero Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Spero Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Spero shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Spero Therapeutics. By using and applying Spero Stock analysis, traders can create a robust methodology for identifying Spero entry and exit points for their positions.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant bacterial infections and rare diseases in the United States. Spero Therapeutics, Inc. has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries collaboration agreement with Bill Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Spero Therapeutics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run CEO Directory Now

   

CEO Directory

Screen CEOs from public companies around the world
All  Next Launch Module
Additionally, take a look at World Market Map. Note that the Spero Therapeutics information on this page should be used as a complementary analysis to other Spero Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Complementary Tools for Spero Stock analysis

When running Spero Therapeutics price analysis, check to measure Spero Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Spero Therapeutics is operating at the current time. Most of Spero Therapeutics' value examination focuses on studying past and present price action to predict the probability of Spero Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Spero Therapeutics' price. Additionally, you may evaluate how the addition of Spero Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Is Spero Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Spero Therapeutics is measured differently than its book value, which is the value of Spero that is recorded on the company's balance sheet. Investors also form their own opinion of Spero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spero Therapeutics' market value can be influenced by many factors that don't directly affect Spero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Spero Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.